We develop T cell-targeted LNPs through antibody, fragment, and pMHC-based surface functionalization combined with immunotropic lipid design, providing end-to-end support from ligand selection and conjugation to formulation, characterization, and cellular and in vivo delivery evaluation.
T cell-targeted LNPs are engineered to deliver nucleic acid payloads selectively to T lymphocytes and defined T cell subsets. Because resting T cells are small, non-phagocytic, and endocytically quiescent, conventional LNPs that accumulate in the liver transfect T cells poorly. T cell-targeted formulations address this by displaying T cell-binding ligands—antibodies directed against CD3, CD4, CD5, CD7, or CD8, antibody fragments such as scFv and VHH, or peptide–MHC (pMHC) complexes—or by re-engineering the lipid composition itself to shift biodistribution toward the spleen, lymph nodes, and circulating lymphocytes. These systems are being investigated for in vivo CAR expression, T cell gene editing, immune regulation, and cancer immunotherapy research.
BOC Sciences provides integrated targeted LNP development for T cell applications, covering targeting ligand selection and synthesis, surface conjugation, immunotropic lipid screening, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support customized LNPs carrying mRNA, siRNA, miRNA, plasmid DNA, and genome-editing payloads, with the targeting architecture matched to the intended T cell population, payload, and administration route.
T Cell-Targeted Lipid Nanoparticle IllustrationOur development services combine lipid chemistry, ligand engineering, nanoparticle formulation, and immunology-oriented evaluation to address the specific barriers of T cell delivery. Projects can begin with an existing LNP formulation, a candidate targeting antibody, or only a delivery objective—such as achieving pan-T cell transfection or selectively engaging a defined subset. We customize the development scope according to payload properties, target-cell phenotype, and the intended administration route.
We investigate how ionizable lipid structures and supporting lipid components influence T cell binding, intracellular delivery, and lymphoid tissue distribution.
We develop ligand-functionalized LNPs that engage T cell surface markers while controlling the immunological consequences of ligand binding. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended T cell-delivery application.
We evaluate particle attributes alongside T cell-specific delivery and functional payload expression to identify whether targeting modifications translate into biologically meaningful transfection.
T cell-targeted LNPs can be developed through receptor-specific surface functionalization, lipid composition engineering, or antigen-specific recognition. The selection of a suitable strategy depends on whether the objective is broad T cell delivery, selective delivery to CD4+ or CD8+ populations, or genetic modulation of antigen-specific T cells. BOC Sciences supports the development and comparison of these targeting architectures.
Antibody-functionalized LNPs use surface-displayed antibodies to recognize receptors expressed across broad T cell populations. Anti-CD3 is a representative approach for engaging T cells through the TCR-CD3 complex, while CD2 and CD7 provide alternative receptor-targeting options with different internalization characteristics. These approaches can improve LNP association and nucleic acid delivery compared with unmodified particles.
Research reference: Anti-CD3-conjugated LNPs for T cell mRNA delivery and activation (Biomaterials, 2022); comparative CD2/CD4/CD5/CD7/CD8-targeted LNP evaluation for T cell mRNA delivery (Journal of Controlled Release, 2026).
CD4- and CD8-directed LNPs are designed to deliver nucleic acids to distinct T cell populations according to their surface marker expression. CD4-targeted systems are relevant to helper and regulatory T cell research, whereas CD8-targeted systems support studies involving cytotoxic T lymphocytes. The targeting ligand and LNP composition must be selected according to the intended T cell subset and its receptor internalization behavior.
Research reference: CD4-antibody-functionalized mRNA-LNPs for selective T cell genetic recombination, including approximately 60% splenic and 40% lymph-node CD4+ T cell recombination in a reported mouse model (Molecular Therapy, 2021); CD8-targeted mRNA-LNPs for in vivo CAR T cell engineering (Molecular Therapy, 2026).
Lipid-engineered LNPs modify tissue distribution through changes in ionizable lipid structures and supporting lipid composition. Rather than relying entirely on surface ligands, this approach investigates how lipid headgroups, hydrophobic tails, PEG-lipid content, and particle surface properties influence extrahepatic delivery and accumulation in lymphoid organs. Such formulations can provide a useful foundation for subsequent T cell-specific surface functionalization.
Research reference: Extrahepatic-tropic ionizable LNPs with antibody functionalization for in vivo mRNA CAR T cell engineering (Small, 2024).
pMHC-functionalized LNPs use peptide-major histocompatibility complex molecules displayed on the particle surface to recognize antigen-specific T cells through their corresponding TCRs. Unlike conventional antibody-based targeting, this approach uses antigen recognition to distinguish T cells with specific TCR profiles. pMHC class I and class II structures can be selected according to the intended CD8+ or CD4+ T cell population.
Research reference: pMHC class II-functionalized LNPs for selective mRNA delivery to antigen-specific CD4+ T cells, including in vivo delivery and CAR expression (ACS Applied Materials & Interfaces, 2026).
Share your payload and target T cell population. BOC Sciences can help evaluate feasible targeting options, synthesize and conjugate relevant ligands, and develop a comparative formulation strategy.
BOC Sciences develops T cell-targeted LNPs for the payload classes most frequently studied in T cell-directed delivery research. Each payload requires a matched loading strategy, particle design, and functional readout, and we help connect the targeting architecture with payload-specific formulation requirements.
| Payload Type | Supported Uses & T Cell-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| T Cell-Targeted LNP for mRNA | Designed for reporter expression, CAR and TCR expression research, cytokine and immune-modulator expression studies. Development focuses on mRNA integrity, nucleoside modification compatibility, T cell transfection, and expression kinetics in activated versus resting T cells, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| T Cell-Targeted LNP for siRNA | Suitable for gene-knockdown studies in T cell models, including pathway and checkpoint-related silencing research. Development evaluates siRNA encapsulation, target silencing in T cells, and selectivity of uptake against non-T cell populations, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| T Cell-Targeted LNP for miRNA | Applicable to miRNA replacement and inhibition studies addressing T cell differentiation, exhaustion, and immune regulation. Development considers miRNA loading behavior, intracellular availability, and functional readouts in T cell subset models, supported by our lipid nanoparticles for miRNA delivery services. | Inquiry |
| T Cell-Targeted LNP for Cas9 mRNA and sgRNA | Designed for genome-editing research in T cells, where transient Cas9 expression and repeat-dosing capability are key advantages of LNP delivery. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in T cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| T Cell-Targeted LNP for circRNA and saRNA | Designed for payloads that require strong protection and extended expression in T cells. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in T cell models, supported by our lipid nanoparticles for circRNA delivery and lipid nanoparticles for saRNA delivery platforms. | Inquiry |
| T Cell-Targeted LNP for ASO | Suitable for splice-modifying and knockdown oligonucleotide research in T cell models. Development focuses on oligonucleotide loading, nuclear delivery, and uptake comparison across T cell subsets, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| T Cell-Targeted LNP for Protein and Peptide | Applicable to cytokines, immune-modulating proteins, and peptide payloads, including proteins co-displayed on the particle surface alongside targeting ligands. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| T Cell-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map T cell uptake, subset-level engagement, and in vivo distribution trends across spleen, lymph nodes, and blood, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| T Cell-Targeted LNP for Custom Payload | Developed for unusual payloads, co-delivery systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, targeting modification route, particle stability, and delivery performance in the agreed T cell models. | Inquiry |
Tell us your payload, target T cell population, and delivery goal, and BOC Sciences will propose a targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate targeting antibody, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and biological evidence becomes available.

We review the payload class, the intended T cell population—pan-T, CD4⁺ helper, CD8⁺ cytotoxic, regulatory, or antigen-specific clones—whether resting or activated cells are the target, baseline LNP formulations if available, and desired biological readouts. These inputs define the starting materials, comparator models, and the screening plan.

We propose candidate ionizable lipids, helper lipid balances, and PEG-lipid architectures, then select the targeting layer—antibody or fragment display, lipid-intrinsic lymphoid tropism, or pMHC engagement. Ligand chemistry, spacer design, and target density ranges are defined at this stage, and each design includes matched non-targeted and isotype-conjugated control LNPs.

Candidates are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, ligand density, and payload retention. During LNP process optimization, we adjust composition, antibody input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds.

Selected candidates are evaluated in T cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, CAR surface presentation, or gene knockdown. Combined nanoparticle cellular & in vivo evaluation then compares splenic and lymph node T cell transfection against hepatic and splenic red-pulp accumulation, with activation and phenotype markers monitored in parallel. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
A T cell-targeted LNP may be well characterized chemically yet still deliver mostly to the liver, transfect resting T cells inefficiently, or activate the very cells it is meant to reprogram. We investigate formulation and immunological factors together and use matched comparison studies to identify the step limiting performance.
✔ Hepatic Clearance and Poor Lymphoid Tissue Delivery
ApoE adsorption and LDL receptor-mediated uptake draw conventional LNPs into hepatocytes, leaving limited exposure for splenic and lymph node T cells. We compare ionizable lipid structures, anionic and SORT-style helper lipids, and PEG-lipid densities to shift biodistribution, and quantify splenic and circulating T cell transfection for every candidate rather than relying on total expression data.
✔ Low Uptake and Endosomal Escape in Resting T Cells
Resting T cells are endocytically quiescent, so ligand-bound particles often accumulate without productive transfection. We measure ligand exposure alongside receptor internalization, compare intracellular localization with functional expression readouts, and apply LNP endosomal escape evaluation to determine whether the limitation sits at uptake or at endosomal release before reformulating.
✔ Ligand-Induced T Cell Activation, Depletion, and Cytokine Effects
Anti-CD3 and other activating ligands can transiently deplete target subsets, downregulate the targeted receptor, and trigger cytokine release at high coating densities. We screen ligand identity—comparing CD3, CD5, CD7, and fragment-based alternatives—and coating density against activation-marker and cytokine readouts, and use LNP transfection troubleshooting services to separate density-driven immunological effects from formulation-driven ones.
✔ Subset Specificity and Distribution Variability Across Spleen, Lymph Nodes, and Blood
Delivery can differ widely between splenic, nodal, and circulating T cell compartments and between CD4⁺ and CD8⁺ subsets. We use labeled particles and subset-resolved flow cytometry to map where payload expression actually occurs, supported by nanoparticle in vivo distribution analysis, then adjust ligand density, composition, and design variables to reduce variability across the intended populations.
Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.
T cell-targeted LNPs provide a nonviral approach for delivering genetic payloads to selected T cell populations. Current research focuses on in vivo CAR T cell engineering, gene editing, antigen-specific immune-cell modulation, and cancer immunotherapy. BOC Sciences supports customized LNP development for these applications, connecting targeting ligand selection and lipid engineering with payload formulation and functional delivery evaluation.
Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate T cell-targeted LNPs tailored to your project.
We connect ionizable lipid structure, supporting lipid composition, and particle surface properties with T cell delivery performance. Our screening approach considers receptor-mediated uptake, intracellular release, and tissue distribution to help identify lipid architectures suitable for different T cell populations.

Our development capabilities cover antibody and antibody-fragment modification, receptor-binding ligand selection, pMHC surface display, lipid-anchor conjugation, and multivalent surface engineering. Ligand orientation, density, and accessibility are considered together to support the intended T cell targeting mechanism.
We develop LNP formulations according to the structural and functional requirements of mRNA, siRNA, pDNA, circRNA, and CRISPR-related payloads. Lipid composition, encapsulation parameters, mixing conditions, and surface modifications are optimized together to maintain particle properties and payload integrity.
Our evaluation workflows combine physicochemical characterization, T cell uptake, functional payload delivery, cellular viability, activation-related readouts, and tissue distribution analysis. This integrated approach helps distinguish particle association from functional transfection and identify limitations at different stages of delivery.
From initial target selection and lipid design to ligand synthesis, LNP formulation, characterization, and biological evaluation, BOC Sciences coordinates the major development stages within one project framework. This helps connect targeting chemistry, nanoparticle properties, and functional delivery results throughout formulation development.
T cell-targeted LNPs are designed to improve delivery to selected T lymphocytes rather than relying only on nonspecific particle uptake. Conventional LNPs can show substantial liver accumulation and may enter immune-cell populations unevenly. Targeted systems add a recognition layer, such as an antibody or pMHC complex, and may also use lipid compositions selected to influence lymphoid tissue distribution. The appropriate design depends on whether the goal is broad T cell delivery, CD4+ or CD8+ subset delivery, or antigen-specific recognition. BOC Sciences supports lipid screening, ligand functionalization, formulation optimization, and cellular and evaluation. Importantly, receptor binding alone does not establish functional transfection.
Potential targets include CD3, CD4, CD5, CD7, and CD8; CD2 has also been explored in comparative receptor-targeting studies. CD3 can engage a broad T cell population, while CD4 and CD8 can guide designs toward corresponding subsets. CD5 and CD7 offer additional receptor-directed options, but their suitability depends on expression, internalization behavior, and distribution across target and non-target cells. For antigen-specific targeting, pMHC molecules can engage matching T cell receptors rather than simply recognizing a lineage marker. BOC Sciences can help compare ligand identity, conjugation chemistry, orientation, and surface density. Selection should also account for potential receptor signaling or T cell activation.
Evaluation should separate four stages: particle quality, cell association, internalization, and functional payload activity. Particle characterization typically includes size, PDI, zeta potential, morphology, encapsulation efficiency, and payload integrity. Flow cytometry or imaging can compare uptake in CD4+, CD8+, and other relevant populations, ideally with non-targeted LNP controls. Functional readouts depend on payload and may include reporter expression, CAR expression, gene knockdown, or editing outcomes. Cell viability, activation markers, and cytokine profiles help identify unwanted biological effects. For systemic studies, tissue distribution in blood, spleen, lymph nodes, and liver should be assessed alongside cell-resolved delivery.
Potential payloads include mRNA for transient protein expression, siRNA for gene silencing, plasmid DNA for genetic expression studies, circRNA for sustained expression research, and CRISPR-related components such as Cas9 mRNA and guide RNA. These payloads differ in size, structure, charge, and intracellular requirements, so one formulation should not be assumed to fit all. Development may involve adjusting lipid-to-payload or N/P ratios, mixing conditions, buffer composition, and loading sequence. BOC Sciences can tailor formulation and characterization to the selected payload and evaluate the corresponding functional endpoint in relevant T cell models.
Selective delivery can be limited by differences in receptor abundance and internalization among T cell subsets, as well as changes associated with resting, activated, or memory states. Systemic LNPs may also accumulate in the liver or distribute to other immune cells before reaching the intended T cells. Even after uptake, endosomal trapping can prevent cytosolic release and reduce payload activity. Some targeting ligands, especially those engaging signaling receptors, may alter T cell activation, receptor expression, viability, or cytokine release. Optimization therefore needs matched controls and cell-resolved readouts, not uptake alone. BOC Sciences can investigate lipid composition, ligand density, receptor choice, and intracellular delivery together.